In addition, the composite of cardiovascular death or HF hospitalizations/urgent visits was significantly reduced in patients treated with SGLT2 inhibitors stratified by age, sex, race, renal function, HF functional classification, ejection fraction, and in those with or without diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.